Bortezomib downregulated CIP2A, phospho-Akt (P-Akt) and phospho-4EBP1 (P-4EBP1) in a dose- and time-dependent manner in all tested HCC cells. The gene discussed is EIF4EBP1; the disease is hepatocellular carcinoma.